↓ Skip to main content

Dove Medical Press

Article Metrics

Update on the emerging role of telavancin in hospital-acquired infections

Overview of attention for article published in Therapeutics and Clinical Risk Management, April 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
17 Mendeley
Title
Update on the emerging role of telavancin in hospital-acquired infections
Published in
Therapeutics and Clinical Risk Management, April 2015
DOI 10.2147/tcrm.s57376
Pubmed ID
Authors

Obinna Nnedu, George Pankey

Abstract

Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus and non-Van-A strains of vancomycin-resistant enterococci. It has been approved by the US Food and Drug Administration (FDA) for complicated skin and skin structure infections and hospital-acquired pneumonia. There is a need for more clinical studies to determine the role of telavancin in treating bacteremia and prosthetic device infections. In this review, we discuss the published data on the use of telavancin in treating hospital-acquired infections and provide an update on new research.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 17 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 24%
Researcher 4 24%
Lecturer 1 6%
Student > Doctoral Student 1 6%
Professor > Associate Professor 1 6%
Other 0 0%
Unknown 6 35%
Readers by discipline Count As %
Medicine and Dentistry 7 41%
Agricultural and Biological Sciences 1 6%
Business, Management and Accounting 1 6%
Immunology and Microbiology 1 6%
Environmental Science 1 6%
Other 0 0%
Unknown 6 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2015.
All research outputs
#12,487,930
of 14,123,042 outputs
Outputs from Therapeutics and Clinical Risk Management
#928
of 1,007 outputs
Outputs of similar age
#189,717
of 228,766 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#17
of 19 outputs
Altmetric has tracked 14,123,042 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,007 research outputs from this source. They receive a mean Attention Score of 4.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,766 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.